EUVIMEDEUVIMED entdecken
Open Access

Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma

Yasunobu Sekiguchi, Hiroki Tsutsumi, Ayumi Gomyo, Masahisa Kudo, Yoshie Iizaki, Nobuo Maseki, Machiko Kawamura, Kazuhiko Kobayashi, Yu Nishimura, Hiroaki Kanda, Hideaki Nitta, Masaaki Noguchi und 1 weitere

Journal of Clinical and Experimental Hematopathology · 26.12.2023 · 63 (4) · 262-265

DOI: 10.3960/jslrt.23043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematopathology, erschienen am 26.12.2023. Verfasst von Yasunobu Sekiguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Saitama Cancer Center, Saitama, Japan. Hauptthemen laut MEDLINE: Immunoconjugates, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesLymphoma, Large B-Cell, DiffuseHumansAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsRituximab

Stichwörter der Autor:innen

80 years overPOLARIXPola-R-mini-CHPR-mini-CHOPdiffuse large B-cell lymphoma

Substanzen

polatuzumab vedotinAntibodies, MonoclonalImmunoconjugatesRituximab

Autor:innen und Institutionen

  • Department of Hematology, Saitama Cancer Center, Saitama, Japan.
  • Department of Clinical Laboratory Medicine, Saitama Cancer Center, Saitama, Japan.
  • Department of Inspection Engineering, Saitama Cancer Center, Saitama, Japan.
  • Department of Pathology, Saitama Cancer Center, Saitama, Japan.
  • Department of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.

Zitieren

APA

Sekiguchi, Y., Tsutsumi, H., Gomyo, A., Kudo, M., Iizaki, Y., Maseki, N., Kawamura, M., Kobayashi, K., Nishimura, Y., Kanda, H., Nitta, H., Noguchi, M., & Kobayashi, H. (2023). Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology, 63(4), 262-265. https://doi.org/10.3960/jslrt.23043

Vancouver

Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Iizaki Y, Maseki N, et al. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. 2023;63(4):262-265. doi:10.3960/jslrt.23043

BibTeX
@article{Sekiguchi2023,
  author = {Sekiguchi, Yasunobu and Tsutsumi, Hiroki and Gomyo, Ayumi and Kudo, Masahisa and Iizaki, Yoshie and Maseki, Nobuo and Kawamura, Machiko and Kobayashi, Kazuhiko and Nishimura, Yu and Kanda, Hiroaki and Nitta, Hideaki and Noguchi, Masaaki and Kobayashi, Hirofumi},
  title = {Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma},
  journal = {Journal of Clinical and Experimental Hematopathology},
  year = {2023},
  volume = {63},
  number = {4},
  pages = {262--265},
  doi = {10.3960/jslrt.23043}
}
Kostenlos starten →